NGL Fine-Chem enterprise value

Share price at each year-end

Tap a line for its trend	Currentlast 12M	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023


1,613	—	—	—	—
42.0	42.0	60.2	54.0	47.3
108	108	73.2	32.4	30.5
1,679	—	—	—	—
66.4	66.4	12.9	−21.5	−16.8
₹2,718.13	—	—	—	—

438	438	356	295	253
24.8%	24.8%	20.6%	11.0%	12.0%
0.06×	—	—	—	—

3.13×	—	—	—	—
19.95×	—	—	—	—
26.40×	—	—	—	—
536	501	368	339	278
84.2	72.7	33.9	53.3	34.3
63.6	53.1	21.4	41.6	23.0
—	43.3	35.8	20.5	35.3
−46.5	−46.5	−94.9	−8.1	3.9
—	−47.6	−95.5	−8.4	4.1
—	89.9	131	28.5	31.4

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

NGLFINE₹2,610.60

NGL Fine-Chem Limited

· Pharma & Health

₹ CrorePeersSYNCOMF JAGSNPHARM HESTERBIOAMRUTANJAN WINDLAS INDOCO SAIPARENTMcap ₹1,613 Cr

HighlightsEnterprise Value Multiples Per ShareAnnuals · FY-end closes

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Current/LTM TTM · last close
Market Capitalization	—	—	—	—	1,612.8
- Cash, Equiv & ST Investments	47.3	54.0	60.2	42.0	42.0
+ Total Debt	30.5	32.4	73.2	108.4	108.4
Enterprise Value	—	—	—	—	1,679.3
Net Debt (memo)	-16.8	-21.5	12.9	66.4	66.4
EV per Share	—	—	—	—	2,718.13

Total Capital	253.0	295.1	355.6	437.7	437.7
Total Debt/Total Capital	12.05	10.99	20.57	24.77	24.77
Total Debt/EV	—	—	—	—	0.06

EV/Sales	—	—	—	—	3.13
EV/EBITDA	—	—	—	—	19.95
EV/EBIT	—	—	—	—	26.40
Reference Items — Trailing FY Values
Sales	278.1	338.7	368.3	501.0	536.2
EBITDA	34.3	53.3	33.9	72.7	84.2
EBIT	23.0	41.6	21.4	53.1	63.6
Operating Cash Flow	35.3	20.5	35.8	43.3	—
Free Cash Flow	3.9	-8.1	-94.9	-46.5	-46.5
FCFF (free cash flow to the firm)	4.1	-8.4	-95.5	-47.6	—
Capital Expenditure	31.4	28.5	130.8	89.9	—

Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.